Short‐term Effect of Verapamil on Coronary No‐Reflow Associated With Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Authors:
- 7 June 2013
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 36 (8) , E11-E16
Abstract
Background: To evaluate the clinical efficacy and safety of intracoronary verapamil injection in the prevention and treatment of coronary no‐reflow after percutaneous coronary intervention (PCI).Hypothesis: Intracoronary verapamil injection may be beneficial in preventing no‐reflow/slow‐flow after PCI.Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials database. Randomized trials comparing the efficacy and safety of intracoronary verapamil infusion vs control in patients with acute coronary syndrome (ACS) were included. Meta‐analysis was performed by RevMan 5.0 software (Cochrane Collaboration, Copenhagen, Denmark) .Results: Seven trials involving 539 patients were included in the analysis. Verapamil treatment was significantly more effective in decreasing the incidence of no‐reflow (risk ratio [RR]: 0.33; 95% confidence interval [CI]: 0.23 to 0.50) as well as reducing the corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC) (weighted mean difference: −11.62; 95% CI: −16.04 to −7.21) and improving the TIMI myocardial perfusion grade (TMPG) (RR: 0.43; 95% CI: 0.29 to 0.64). Verapamil also reduced the 30‐day wall motion index (WMI) compared to the control. Moreover, the procedure reduced the incidence of major adverse cardiac events (MACEs) in ACS patients during hospitalization (RR: 0.37; 95% CI: 0.17 to 0.80) and 2 months after PCI (RR: 0.56; 95% CI: 0.33 to 0.95). However, administration of verapamil did not provide an additional improvement of left ventricular ejection fraction regardless of the time that had passed post‐PCI.Conclusions: Intracoronary verapamil injection is beneficial in preventing no‐reflow/slow‐flow, reducing CTFC, improving TMPG, and lowering WMI. It is also likely to reduce the 2‐month MACEs in ACS patients post‐PCI.Keywords
This publication has 16 references indexed in Scilit:
- REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER)American Heart Journal, 2012
- Predictors and Long‐term Prognosis of Angiographic Slow/No‐Reflow Phenomenon During Emergency Percutaneous Coronary Intervention for ST‐Elevated Acute Myocardial InfarctionClinical Cardiology, 2010
- The pathogenesis and treatment of no-reflow occurring during percutaneous coronary interventionCardiovascular Revascularization Medicine, 2008
- Importance of Tissue Perfusion in ST Segment Elevation Myocardial Infarction Patients Undergoing Reperfusion Strategies: Role of AdenosineClinical Cardiology, 2007
- Pharmacological Management of No Reflow During Percutaneous Coronary InterventionCurrent Vascular Pharmacology, 2006
- Improvement in Microvascular Reflow and Reduction of Infarct Size With Adenosine in Patients Undergoing Primary Coronary StentingThe American Journal of Cardiology, 2005
- Early Administration of Intracoronary Verapamil Improves Myocardial Perfusion During Percutaneous Coronary Interventions for Acute Myocardial InfarctionChest, 2005
- Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no‐reflow phenomenonCatheterization and Cardiovascular Interventions, 2004
- Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarctionCatheterization and Cardiovascular Interventions, 2002
- Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial InfarctionCirculation, 2000